This article was originally published in The Gray Sheet
Executive SummaryRequirement that patients demonstrate adaquate renal, hepatic, pulmonary and cardiac function in order to be eligible for national coverage for autologous stem cell transplantation (AuSCT) for multiple myeloma is sufficient, and HCFA will not reinstate a cut-off at age 77, the agency decides Feb. 9. Age was to serve as a proxy for predicting who would be susceptible to co-morbidities associated with the procedure; however, HCFA canceled the age restriction Oct. 1, 2000, saying it would try instead to identify specific co-morbidities through an internal review
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.